Geron (GERN) GF Score : 35/100 (As of May. 31, 2024)

View and export this data going back to 1996. Start your Free Trial

What is Geron GF Score?

Geron has the GF Score of 35, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 3/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Geron might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Geron's GF Score

For the Biotechnology subindustry, Geron's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Geron's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geron's GF Score distribution charts can be found below:

* The bar in red indicates where Geron's GF Score falls into.

Geron (NAS:GERN) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Geron GF Score Related Terms

Thank you for viewing the detailed overview of Geron's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Geron (GERN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (NAS:GERN) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

GON:Germany

Address

919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404

Website

https://www.geron.com

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.

Executives

Michelle Robertson	officer: EVP, Chief Financial Officer	C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elizabeth G. O'farrell	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Scott Alan Samuels	officer: EVP, Chief Legal Officer	919 E. HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
V Bryan Lawlis	director
Susan Molineaux	director	C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
John A Scarlett	director, officer: Chief Executive Officer	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Andrew J Grethlein	officer: EVP, Technical Operations	651 GATEWAY BLVD STE 950, SOUTH SAN FRANCISCO CA 94080
Olivia Kyusuk Bloom	officer: Controller, Chief Acctg Off	C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
John F Mcdonald	director	C/O GERON CORPORATION, 919 EAST HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
Faye Feller	officer: EVP, Chief Medical Officer	919 EAST HILLSDALE BOULEVARD, SUITE 250, FOSTER CITY CA 94404
Anil Kapur	officer: EVP, Corp Strategy & CCO	275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Melissa Kelly	officer: VP, Oncology	230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Dawn Carter Bir	director	C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Aleksandra Rizo	officer: EVP, Chief Medical Officer	C/O GERON CORPORATION, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025